-
公开(公告)号：US20200317751A1
公开(公告)日：2020-10-08
申请号：US16886057
申请日：2020-05-28
申请人： Kymab Limited
IPC分类号： C07K16/00
摘要： The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate antibodies or nucleotide sequences encoding antibodies. Antibodies, heavy chains, polypeptides, nucleotide sequences, pharmaceutical compositions and uses are also provided by the invention.
-
公开(公告)号：US10730930B2
公开(公告)日：2020-08-04
申请号：US15656897
申请日：2017-07-21
申请人： Kymab Limited
IPC分类号： A01K67/027 , C12N5/071 , C12N15/63 , A61K39/395 , A01N63/00 , C07H21/04 , C07K16/00 , C07K16/46 , C12N15/85
摘要： The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate antibodies or nucleotide sequences encoding antibodies. Antibodies, heavy chains, polypeptides, nucleotide sequences, pharmaceutical compositions and uses are also provided by the invention.
-
公开(公告)号：US20200214274A1
公开(公告)日：2020-07-09
申请号：US16721326
申请日：2019-12-19
申请人： Kymab Limited
IPC分类号： A01K67/027 , C07K16/18
摘要： The invention relates to cells and non-human vertebrates for producing antibody chains (eg, truly common L or H chains), in particular for use in producing multi-specific antibodies useful for therapy or diagnosis.
-
公开(公告)号：US20200148787A1
公开(公告)日：2020-05-14
申请号：US16625109
申请日：2018-06-22
申请人： KYMAB LIMITED
摘要： Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.
-
公开(公告)号：US10226033B2
公开(公告)日：2019-03-12
申请号：US15690183
申请日：2017-08-29
申请人： Kymab Limited
发明人： Allan Bradley , E-Chiang Lee , Qi Liang , Wei Wang , Dominik Spensberger , Hui Liu , Jasper Clube
IPC分类号： A01K67/027 , A61K39/00 , C07H21/04 , C12N5/07 , C12N15/63 , C07K16/06 , C07K16/12 , C07K16/18 , C07K16/46 , C12N15/85
摘要： The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanized antibodies; compositions comprising the antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in the methods.
-
公开(公告)号：US10064398B2
公开(公告)日：2018-09-04
申请号：US14516461
申请日：2014-10-16
申请人： Kymab Limited
发明人： Allan Bradley , E-Chiang Lee , Qi Liang , Wei Wang , Glenn Friedrich
摘要： The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanized antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
-
公开(公告)号：US09783593B2
公开(公告)日：2017-10-10
申请号：US13875892
申请日：2013-05-02
申请人： Kymab Limited
CPC分类号： C07K16/00 , A01K67/0278 , A01K2217/072 , A01K2217/075 , A01K2227/105 , C07K16/46 , C07K16/462 , C12N15/8509
摘要： The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate antibodies or nucleotide sequences encoding antibodies. Antibodies, heavy chains, polypeptides, nucleotide sequences, pharmaceutical compositions and uses are also provided by the invention.
-
公开(公告)号：US20160257974A1
公开(公告)日：2016-09-08
申请号：US15072978
申请日：2016-03-17
申请人： Kymab Limited
发明人： Allan Bradley , Hanif Ali , E-Chiang Lee
IPC分类号： C12N15/90 , C07K16/00 , C12N15/10 , A01K67/027
CPC分类号： C12N15/102 , A01K67/0278 , A01K2207/15 , A01K2217/052 , A01K2217/072 , A01K2227/105 , A01K2267/01 , C07K16/00 , C07K2317/14 , C07K2317/20 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C12N5/0635 , C12N15/907 , C12N2510/04 , C12N2800/80
摘要： The invention relates to an approach for introducing one or more desired insertions and/or deletions of known sizes into one or more predefined locations in a nucleic acid (e.g., in a cell or organism genome). They developed techniques to do this either in a sequential fashion or by inserting a discrete DNA fragment of defined size into the genome precisely in a predefined location or carrying out a discrete deletion of a defined size at a precise location. The technique is based on the observation that DNA single-stranded breaks are preferentially repaired through the HDR pathway, and this reduces the chances of indels (e.g., produced by NHEJ) in the present invention and thus is more efficient than prior art techniques. The invention also provides sequential insertion and/or deletions using single- or double-stranded DNA cutting.
-
公开(公告)号：US09434782B2
公开(公告)日：2016-09-06
申请号：US14137902
申请日：2013-12-20
申请人： Kymab Limited
发明人： Allan Bradley , E-Chiang Lee , Qi Liang , Wei Wang , Glenn Friedrich
CPC分类号： A01K67/0278 , A01K67/0271 , A01K67/0275 , A01K67/0276 , A01K2207/15 , A01K2217/072 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/01 , A61K39/107 , A61K39/35 , A61K2039/505 , C07K16/00 , C07K16/1203 , C07K16/1239 , C07K16/18 , C07K16/462 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12N15/8509 , C12N2015/8518
摘要： The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanized antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
摘要翻译： 本发明公开了产生嵌合人非 - 人抗体和嵌合抗体链，如此制备的抗体和抗体链的方法及其衍生物，包括完全人源化抗体; 包含适合用于所述方法的所述抗体，抗体链和衍生物的组合物，以及细胞，非人哺乳动物和载体。
-
90.发明申请公开(公告)号：US20150037337A1
公开(公告)日：2015-02-05
申请号：US14220095
申请日：2014-03-19
申请人： Kymab Limited
发明人： Glenn Friedrich , E-Chiang Lee , Jasper Clube , Nicholas England
CPC分类号： C07K16/468 , C07K16/00 , C07K2317/51 , C07K2317/515 , C07K2317/565 , G01N33/5005 , G01N33/5052 , G01N33/569
摘要： The invention provides improved non-human vertebrates and non-vertebrate cells capable of expressing antibodies comprising human variable region sequences. The present invention is directed to the provision of long HCDR3s from non-human vertebrates and cells. The present invention is also directed to the provision of novel V, D and J pairings in immunoglobulin heavy and light chain loci. Novel, biased antibody diversities and potentially expanded diversities are provided. The invention also provides for novel and potentially expanded diversity or diversity that is biased towards variable gene usage common to antibodies useful for treating and/or preventing certain diseases or conditions, such as infectious diseases. The invention also provides methods of generating antibodies using such vertebrates, as well as the antibodies per se, therapeutic compositions thereof and uses.
摘要翻译： 本发明提供了能够表达包含人可变区序列的抗体的改良的非人脊椎动物和非脊椎动物细胞。 本发明涉及从非人类脊椎动物和细胞提供长HCDR3。 本发明还涉及在免疫球蛋白重链和轻链基因座中提供新的V，D和J配对。 提供了新颖的，有偏见的抗体多样性和潜在扩大的多样性。 本发明还提供了对可用于治疗和/或预防某些疾病或病症（例如感染性疾病）的抗体的可变基因使用的偏向于可变基因使用的新型和潜在扩展的多样性或多样性。 本发明还提供了使用这种脊椎动物产生抗体的方法，以及抗体本身，其治疗组合物和用途。
-
-
-
-
-
-
-
-
-
搜索结果
93 条记录 (耗时 0.054 秒)
